



Sankalp India Foundation®

Let's Give Life A Better Chance

# ANNUAL REPORT

## 2024-25



+91-9480044444 | [www.sankalpindia.net](http://www.sankalpindia.net) | [contact@sankalpindia.net](mailto:contact@sankalpindia.net)  
3rd Floor, GRACE MAYUR #32, Millers Tank Bund Road, Opposite Bhagwan  
Mahaveer Jain Hospital, Vasanthnagar, Bengaluru - 560052



This past year, Sankalp has not just grown, it has soared.

In Prevention, we're rewriting the future: screening over **1.25 lakh** pregnant women across 80 districts in 5 states, nearly doubling our reach from 44 districts. For every 1,000 women enrolled, we're preventing one child from being born with the disease, covering **1%** of all births in India.


In Management, we expanded our day care network with **4** new centres in Shimoga, Parbhani, Guntur, and Bhavnagar. Our Blood Centre delivered **72.7%** of its collected units specifically to thalassemia patients, strengthening the lifeline for those in need.

In Cure, our bone marrow transplant program surged from 14 to **31** beds—with 21 in Bangalore and 10 at our new Health1 facility in Ahmedabad. Meanwhile, Sankalp Labs **tripled** its reach, driving progress with advanced diagnostics at the heart of our mission.

Imagine a world where every child is born with a fighting chance—a world free from the shadows of thalassemia and sickle cell disease.

Imagine a nation where blood flows freely, not out of obligation, but from the heart of a united community.

At Sankalp India Foundation, we don't just imagine this world. We're forging it, standing boldly at the frontiers of thalassemia prevention, management, and cure. With passion, practicality, and a relentless drive, we're giving **life a better chance**. And we invite you to walk with us.







These aren't just numbers—they're lives transformed, families uplifted, and a nation inching closer to a thalassemia- and sickle-free horizon.

We're at the forefront, blending science with soul—publishing breakthrough papers, sharpening quality systems, and amplifying our voice with the return of our monthly newsletter Sankalp Patrika in January 2025.

Behind all of it is a team ignited by purpose, honed by agile leadership, and uplifted by partners, donors, and volunteers.

Yet, the frontier stretches further. More hands, more blood, more resources: we need them to accelerate this journey to end unnecessary suffering for all. This annual report isn't just a record of progress, it's an invitation to join a movement that blends into the spirit of life itself. Will you step up with us?

Together, let's turn a bold vision into lasting victory.

Vande Mataram

*Team Sankalp*





## Index

Voluntary Blood Donation	3
Sankalp Program for Thalassemia and Sickle Cell Disease Management	12
Sankalp Program for Cure	19
Sankalp Program for Hemoglobinopathies Prevention	27
Sankalp Labs	34
Sankalp Hemoglobinopathy Academy of Learning (SHeAL)	38
Our Research	41
Our Publications	43
People & Culture	45
Touching Hearts, One Smile at a Time	47
Our Donors	48
Transparency Disclosures	49
Our Financials	50
Join in the Revolution	51



# Voluntary Blood Donation

Enabling safe and sufficient blood access for patients across India



## Overview

Since its inception, Sankalp India Foundation has been committed to promoting 100% voluntary blood donation. Recognizing blood as a critical and often scarce resource for thalassemia patients and others in need, Sankalp has consistently worked to improve access to safe and adequate blood through organized donation efforts and systemic improvements in the blood ecosystem.

## Year in Numbers: 2024-2025



Reach &  
Impact

**22**

cities

**12** states



Blood donation  
drives conducted

**331**



Total Blood  
Collection

**17,369**

units



Sankalp Blood  
Centre Collection

**12,265**

units

Every unit of blood collected through a voluntary donor is a lifeline for a patient in need.


Our mission has always been to ensure that this gift of life is 100% voluntary, easily available, safe, and sufficient."

- Team Sankalp






## Mission in Motion



## Community Engagement & Mobilization

The Foundation's volunteer-driven approach was key to mobilizing communities:

- Partnerships with colleges, corporates, NGOs, and resident welfare associations
- Use of digital platforms for awareness, registration, and follow-up
- Special events on World Blood Donor Day and National Voluntary Blood Donation Day



## Promoting 100% Voluntary Blood Donation

Sankalp actively advocates for completely voluntary, non-remunerated blood donation, shunning replacement or paid donations.

In 2024-25, the Foundation:

- Focused on education and awareness through both digital and on-ground campaigns
- Emphasized first-time donor engagement and repeat donation culture
- Ensured stringent quality control and blood safety protocols

## Impact on Thalassemia Care

Every unit collected contributes to the lifesaving transfusions for children with thalassemia, supported by Sankalp's Day Care Centres and the BMT units across India.


- **72.7%** of all blood issued—**14,488** units—went to support thalassemic children, many in remote centres where our supply is their only lifeline for timely transfusions.
- We have strong partnerships with blood centres and hospitals across 6 states



At every camp, we ensure that donors are informed, screened, and appreciated - because their contribution is the cornerstone of transfusion safety

Sankalp Blood Centre  
Team





## Sankalp Blood Centre: A Hub for Quality and Innovation

Sankalp Blood Centre is a project of Sankalp India Foundation in association with


**Jai Shivshakti Health and Educational Foundation** and **Karnataka Marwari Youth Federation**.

Cosponsored by:


- **Avon Plastic Industries Private Limited**
- **Goodrich Aerospace Services Pvt. Ltd.**
- **Sansera Foundation**
- **Micro Labs Limited**
- **Suprajit Foundation**
- **Mahindra CIE Automotive Limited**

The Sankalp Blood Centre, operating with a fully automated infrastructure, plays a central role in safe blood collection, processing, and distribution.

- **498 units** collected in-house
- Only non-governmental centre in the country to cryopreserve red blood cells
- Serves as a model for quality assurance in voluntary blood donation
- Issues antibody screened blood to **15** children across country




# Journey so far



# Getting involved

There is still a gap of 1000+ units of blood every month to support thalassemic children under our care and you can help us bridge the gap. Organise a drive today!





## From the Frontlines

“Sankalp India Foundation, in partnership with KMYF, is unwavering in its commitment to the "Patients First" principle. Our dedicated team of compassionate staff and volunteers work tirelessly around the clock.

Mr Rahul Mehta  
Karnataka Marwari Youth Federation

“Sankalp is growing beautifully: more blood collected, more BMT beds, and more scope to learn and contribute. That's what inspired me to join.

Dr. Ashish Dhoot  
Chief Medical Officer  
Sankalp Blood Centre

“I have donated blood before, but the experience of donating at Sankalp is so much better. Knowing that I am making a difference in the lives of these kids makes me want to donate regularly

Prabhu  
Blood Donor

“It was my first time donating blood and the process went so smoothly. Sankalp staff in the camp were very supportive and answered all the doubts. Happy to be part of this camp.

Greeshma S  
Anthology

“Awesome team from Sankalp who make the blood donation camp a great place.

Harish Venkataramanan  
Microsoft

“It was a wonderful experience, the camp started right on time and throughout there were entire teams guiding the donors well. Amazing support!!

Gurudatt Dixit, Senior Manager,  
Customer/Technical Training, Dell  
Technologies

## Thank You for Blood Drives

### Together, We Made Every Drop Count

ACS College Of Engineering  
Agrawal Samaj Karnataka  
AIESEC Mumbai  
Alpine Eco Apartments  
Alpine Pyramid  
Amadeus IT Group  
Anthology Inc.  
Applied Materials India  
Avery Dennison Corp.  
Avon Plastic Industries Pvt. Ltd.  
Bajaj Allianz Life Insurance  
Bajaj Ramjeevanji Charitable  
Trust Gaushala  
Bangalore University  
Bengaluru Malayalees Family  
Club  
Bhartiya Janta Party  
Doddaballapura  
Big Basket  
Biocon Ltd.  
Borderless Access Pvt. Ltd.  
Brick & Bolt Home Construction  
Company  
Brigade Cornerstone Utopia  
Brigade Tech Garden  
Brilyant IT Solutions Pvt. Ltd.  
British Engines India Pvt. Ltd.  
Burns & Mcdonnell India  
Cargill India Pvt. Ltd.  
CB Bhandari Jain College  
CGI Inc.  
Cipla Ltd.  
Cloudera  
Cloudnine Hospitals  
Collins Aerospace  
Conduent Labs  
Customs Office  
D.E. Shaw India Pvt. Ltd.  
Dasarahalli Metro Station  
Dell Technologies  
Deutsche India Pvt. Ltd.  
DHL  
DSR White Waters  
Ecolab Digital Centre  
Electronics for Imaging, Inc.  
Embassy Habitat  
Embassy Heights  
Euro School  
Finwizard Technology Pvt. Ltd.  
Firstsource  
Flipkart Pvt. Ltd.  
Friends Charitable Trust  
Future Generali India Insurance  
Company Ltd.

Fyers Gallagher Insurance  
Brokers Private Limited  
Good Earth Malhar  
Grant Thornton  
Gunjur Govt School  
HDFC Bank  
Himalaya Wellness India  
Huron Consulting Group  
Ibis Hotel  
Icon PLC  
Infosys BPM Ltd.  
Infosys Ltd.  
Ingram Micro  
Innovative Oak Garden  
International Tech Park  
JAA & Associates  
Jawaharlal Nehru Centre For  
Advanced Scientific Research  
Jfrog Ltd.  
Kavach Trust  
KEMS Forgings Ltd.  
Klassik Landmark  
Larsen & Toubro Ltd.  
Mahanth Hospital  
Mahindra and Mahindra  
Financial Services Ltd.  
Makino India Pvt. Ltd.  
Malur Government School  
Mantri Espana  
Masjid E Munawwara  
Mathrushree Kalyana Mantapa  
Mcdonald's Corporation  
Micro Plastics Pvt. Ltd.  
Microsoft Corporation India Pvt.  
Ltd.  
Monarch Serenity  
Mphasis Ltd.  
Nagasandra Metro Station  
National Instruments  
National Law School of India  
University  
Nexus Select Trust  
Novo Nordisk India  
Nurture English School  
Onsite Electro Services Pvt. Ltd.  
OPmobility  
Oracle India Pvt. Ltd.  
PayPal Payments Private  
Limited  
Pegasystems India  
Poornaprajna Resident Welfare  
Association  
Prestige Tech Park  
Quinbay Technologies

R1 Rcm Global Pvt. Ltd.  
Radhakrishna Public School  
Rambus Inc.  
Red Hat Inc.  
Regional Transport Office  
Jnanabharathi  
Robert Bosch Engineering  
Rotary RR Nagar  
RT Nagar Socio Cultural Trust  
( RT Nagar Bengali  
Association)  
Saab Engineering  
Salesforce Inc.  
Sansera Engineering  
Sap Apparels Pvt. Ltd.  
SBI Securities  
Schneider Electric  
SG Lottery India Pvt. Ltd.  
SKF India Ltd.  
SNN Raj Eternia  
Sonestaa Meadows  
Sowparnika Ashiyana  
Sowparnika Life On The Green  
St. Paul's College  
Stryker Corporation  
Sun pharmaceutical  
industries ltd  
Suprajit Engineering Ltd.  
Sushruta Integrative Health  
Care Centre  
SV Brindavanam  
Swastik Foundation  
Tangoe India Softek Services  
Pvt Ltd  
Tata Communications Ltd.  
Tata Consulting Engineers  
Tata Technologies  
The American Express  
Company  
The Executive Centre  
Titan Company Ltd.  
Trelleborg India Pvt. Ltd.  
Uttishta Bharatha  
V The Volunteers  
Vaishnavi Serene  
Varma & Varma Chartered  
Accountants  
Vega City Mall  
Vijayashree Public School  
Vishwa Vidyapeeth School  
Voya India  
Wesco International Inc.  
WeWork India  
Yenepoya University  
Youth For Parivartan

**56 MULTI CITY DRIVES WITH A COLLECTION OF 3352 UNITS OF BLOOD**



## Mapping Impact: Blood Donation Drives

### Our Partners

- Goodera
- Karnataka Marwari Youth Federation
- Healing Touch
- Palms Trust
- Kavach Trust



I was drawn to Sankalp for their inspiring work with thalassemia, providing free blood transfusions and performing cost-effective bone marrow surgeries at scale across India. Their decade-long trust with donors reflects their committed team and strong management. I'm proud to support their advanced blood bank and bone marrow surgery initiatives in Bangalore. Sankalp's ambitious plan to prevent thalassemia births deserves nationwide encouragement and support.

Mr F R Singhvi (KMYF and Sansera Foundation)

### States

Karnataka	Sikkim
Gujarat	Uttarakhand
Tamil Nadu	Madhya Pradesh
Delhi	Telangana
Haryana	Odisha
West Bengal	Maharashtra
Andhra Pradesh	

### Cities

Ahmedabad	Gurgaon	Panoli
Bangalore	Hyderabad	Pantnagar
Bhubaneswar	Indore	Pune
Chandigarh	Jamnagar	Roorkee
Chennai	Kolkata	Sikkim
Coimbatore	Mumbai	Vadodra
Dahej	Mysore	Visakhapatnam
Delhi	Noida	

# Sankalp Program for Thalassemia and Sickle Cell Disease Management

A Holistic Approach to Thalassemia Management





## Brief Overview

We are providing patient-centred medical care to nearly **2,500** underserved children across **6** states and **23** centers, in collaboration with local partners. By leveraging technology, we ensure access to high-quality blood transfusions, medications, diagnostics, and comprehensive medical care.

Through innovation, we ensure **standardized care, regular transfusions, medication support, and family counseling**—so every child receives consistent, high-quality thalassemia management. We are working urgently to expand our reach and impact, while transitioning these children toward a cure.

## Mission & Commitment:

Sankalp India Foundation is committed to ensuring that every child with thalassemia receives **safe, timely, and effective** treatment. Through a robust network of daycare centres, we have set new benchmarks in thalassemia management.

## Year in Numbers: 2024-2025



Total Centres

23

4 New



Total Patients

2,427

From 18 states



Blood Transfusions

42,659

units ↑13.8%



Pre-transfusion Hemoglobin

9.2

mg/dl

Ideal  $\geq 9$

Kids Receiving Double Chelation

51%

Median Ferritin Levels

ng/ml


3,305

Preparing for Cure

310



## Mission in Motion



## Pillars of Progress

### Hemoglobin Management



- We raised our Hb goal to 9.5 gm/dl. **90%** of our kids now stay in the 9–9.5 range.
- This means better growth, fewer complications, and stronger futures.
- **13** daycare centres across India now run on a steady blood supply from Sankalp Blood Centre.

### Towards Chelation Effectiveness



- **>50%** of patients have been put on double chelation.
- Offering personalized financial assistance to children from economically disadvantaged backgrounds to ensure continuous care.

### Double Shifts: More Flexibility for Families



- Double shift transfusions introduced.
- The second shift starting at 11:00 AM allows for greater flexibility and easier access for families traveling from far.





Regional Managers  
- Improved Coordination



- We made operations stronger by introducing more regional managers to ensure **better coordination, training, and streamlined operations.**
- Personalized care for each patient—better monitoring, better results.

Quality Care Quality  
Management System



- We welcomed a new Quality Manager helped establish a **robust Quality Management System.**
- This year, our protocols, workflows, and standards were aligned with the highest industry benchmarks to ensure top-notch care.

Closer Family  
Connection




- We are building stronger relationships with families of thalassemia patients has improved **treatment adherence and overall well-being.**
- We are taking regular feedback and engaging with families across the country directly to understand and address their concerns.

Hydroxyurea Therapy:  
Study and Learning



- 663 children placed on Hydroxyurea therapy, with 195 showing a reduction in transfusion frequency.
- After careful study, discovery of long-term risks like splenomegaly and cardiac issues led to the **discontinuation** of Hydroxyurea therapy.
- Our findings will be shared in international journals for global learning.

Centres And Patients



## The Road Ahead: 2025-26

### Integrated Prevention & Care

We're ensuring that children identified at district hospitals by prevention coordinators are connected to nearby daycare centers or evaluated for curative options

### Strengthening Policy Alignment

We're updating MOUs to define clear roles, responsibilities, and expectations—ensuring transparency, reducing ambiguity, and driving accountable partnerships




### Scaling Chelation Support

We're boosting access to chelation therapy by improving supply chains, reducing costs, and enhancing adherence with patient education and financial aid

### Expanding Blood Access

We're scaling blood collection through strong community and corporate partnerships via Sankalp Blood Centre, ensuring a reliable, safe supply at every daycare centre

## How Can You Contribute to the Cause?





## From the Frontlines

“

Before Sankalp, getting blood was tough. Now the kids get regular care, and it shows. We've got over 100 just in Godhra.

Hiren Bhai  
Godhra

”

“

Most families don't know what thalassemia is. We teach them everything, step by step. Honestly, this work means a lot to me.

Dr. Sujitha  
Doctor  
Sankalp Day Care Bengaluru

”

“

They come in so pale, quiet and tired. A few months later, they're running around. That change? It's the best part.

Poojitha  
Day Care Coordinator  
Bengaluru

”

“

I try to make it just one prick. No fear, no tears-that's my goal. They trust me, and that truly matters.

Nagarathna  
Staff Nurse  
Sankalp Day Care Bengaluru

”

“


जब मैं किसी पेरेंट को समझा कर ये भरोसा दिलाती हूँ कि आपका बच्चा भी बाकी बच्चों की तरह एक अच्छी ज़िंदगी जी सकता है-वो सुकून, वही मेरी सबसे बड़ी जीत है।

Pooja  
Day Care Coordinator  
Jalaram

”



## Mapping Impact: Day Care Centres



To date, we have successfully treated 4,275 patients and administered 252,575 units of blood.

### Our Partners

- IGICH (2011)

KLE's Dr. Prabhakar Kore Hospital & Medical Research Centre, Belagavi (2016)

Rural Development Trust (2016)

Father Muller Medical College and Hospital (2017)

Rughwani Child Health Center (2018)

Shree Jalaram Abhyuday Sadbhavna Trust (2018)

Radha Mohan Mehrotra Global Hospital Trauma Centre (2018)
- Indian Red Cross Society (2019)

Sankalp center (2020)

Tumkur District Hospital (2020)

K J Somaiya (2021)

Rotary Blood Bank (2021)

Rotary Blood Bank (2023)

Mamatha Foundation (2023)

Akola Thalassemia Society (2023)
- Sarthak Seva Foundation (2023)

Shivamogga District Hospital (2023)

Indian Red Cross Society (2023)

Indian Red Cross Society (2024)

District Hospital (2024)

NEEDS Blood Bank (2024)

Sparsh Hospital and (2024)



# Sankalp Program for Cure

A New Era in Thalassemia Cure




## Brief Overview, Mission & Commitment

**Brief Overview:** Sankalp's Cure Project offers children with thalassemia a chance at a transfusion-free life through Bone Marrow Transplantation (BMT). With 730+ BMTs completed across our centres in Bangalore and Ahmedabad, we are making curative care accessible, affordable, and safe.

**Mission:** To deliver high-quality, low-cost BMTs for every eligible child with thalassemia in India.

**Commitment:** We ensure standardized care, donor support, family counseling, and long-term follow-up—so every cure is a step toward a thalassemia-free future.

## Year in Numbers: 2024-2025

 Total Transplants

151 ↑19



Thalassemia/Sickle Cell  
Disease – Matched  
Related Donor

82 ↓1



Thalassemia/Sickle Cell  
Disease –  
Haploidentical Donor

52 ↑17



Fanconi Anemia/Severe  
Aplastic Anemia –  
Matched Related Donor

7 ↑4

Fanconi Anemia/Severe Aplastic  
Anemia – Haploidentical Donor

6 ↓2

Primary Immunodeficiency  
Disorders – Matched Related  
Donor

3 ↑1

Primary Immunodeficiency  
Disorders – Haploidentical Donor

2 ↑1



## Strengthening Systems and Infrastructure

### Reverse exchange

Our nurse visited Vietnam to share transplant best practices.

### New specialties added:

Pediatric endocrinologist at annual follow-ups. Consultant for immune deficiency transplants.

### Hospital Infection Control Committee

Instituted to uphold strict infection standards through the bone marrow transplant journey.

### Protocol enhancements

Peripheral blood stem cell collection now managed on-floor by trained technicians and nurses.

### Global recognition

Observerships hosted for doctors and nurses from Nigeria, Uzbekistan, Africa, Tanzania, Bangladesh, Vietnam.

### Nurse Training

Conducted specialized nurse training program to deliver skilled, compassionate care throughout the bone marrow transplant journey.

## Expanding Our Capacity & Reach

- We shifted to a **new Bone Marrow Transplant Unit (BMT)** for pediatric patients in **Ahmedabad, India funded by DKMS.**
- **Transplant beds expanded** from 14 to 31, making us the **world's largest single pediatric BMT program** focused on Hemoglobinopathies.
- **Cure rate exceeds 95%** for matched related sibling donor transplants with zero GVHD – best-in-class global outcomes.
- **Most cost-effective program:**
  - Matched Related Donor BMT: ₹9.5–10 lakhs
  - Haploidentical BMT: ₹14 lakhs
  - 90% of costs covered through fundraising and partnerships.
- **We are proud to have as our esteemed partners and be empanelled by:**
  - **Coal India's Thalassemia Bal Sewa Yojana**
  - **Maharashtra CM Relief Fund**





## Global Alliances

At the heart of our mission to cure children of hemoglobinopathies lies the unwavering support of our global partners. DKMS and Cure2Children Foundation have played a pivotal role in expanding access to bone marrow transplantation, especially for those in resource-limited settings. Their trust, collaboration, and shared vision have been instrumental in making cures accessible and affordable for every child who needs one.

### DKMS

As a reputed non-profit organization dedicated to the fight against blood cancer and other blood disorders, DKMS has been a cornerstone ally in Sankalp's curative journey. Be it through the patient funding program, the support for capacity building or the free HLA typing program, team DKMS has worked as one with us to offer hope and cure to more families than ever before. With DKMS by our side, we've been able to offer hope and healing to more families than ever before.




### Cure2Children Foundation

Cure2Children Foundation has been a vital partner in our mission to deliver curative care, particularly in underserved regions. Their expertise in bone marrow transplantation and commitment to training and infrastructure development helped us establish our BMT unit in Ahmedabad. Through this partnership, we have not only provided cutting-edge treatment to children with blood disorders but also advanced long-term sustainability in care delivery.



## Mission in Motion



## Community Engagement & Support

### HLA Typing & Outreach:

- 5 HLA typing camps conducted (Dahod, Ahmedabad, Jamnagar)
- 90 families underwent HLA typing

### Child Care Home Activities:

- A safe, healing environment for children and caregivers.
- Hosted volunteers and partners including Cipla, Himalaya, Grant Thornton, Deutsche Bank, Titan, Youth for Seva, Goodera, and more.

## Gratitude to Our Champions

Reaching patients nationwide wouldn't have been possible without the dedication of volunteers like: Mr. Laxmikant Pimpalgaonkar, Parbhani, Mr. Vikram, Rajahmundry, Mr. Ravikumar, Khammam, Prashant Jani, Asit Kotak, and Bhupendra Kotak. We would also like to acknowledge the efforts put in by Thalasseemics Gujarat, Jamnagar Thalassaemia Society, Rotary Club of Bhuj Wall City, Rotary Club of Amreli City and Indian Red Cross Society of Dahod and Godhra.

Their commitment has been instrumental in our mission.


## Looking Ahead – Goals for 2025–26

### Improve Partially Matched Donor Transplant Outcomes

Boosting survival rates for hard-to-match patients through innovation

### Focus on Severe Aplastic Anemia (SAA) & Fanconi Anemia Outreach

Prioritizing rare blood disorders for early intervention & cures



### Cure 300+ More Children

300+ children given life-saving transplants—doubling our impact.


### HLA Typing for 1000 Families - in under-served regions

Expanding donor pool with 1000+ HLA-typed families registered.

### Continue Sickle Cell Disease Transplants

Ending SCD suffering with proven transplant success—no breaks

## How Can You Contribute to the Cause?





## From The Frontlines

“

For years, we lived in fear of every transfusion, every test. Today, my child is thalassemia-free- and I finally breathe without worry. Sankalp gave us the gift of a future.

Seema  
(mother of Azkiya)

”

“

I'm the first to see them in pain & send them for the transplant.. I receive them back with a new beginning. That's what makes me feel proud to be a part of Sankalp.

Taniya  
Nurse SIF-BMJH  
Bangalore

”

“

It's such a joy to see these children get cured. Sometimes we have long days of work, but all the tiredness disappears on seeing the smile of a cured child.

uficca  
BMT Head Nurse SIF-BMJH  
Bangalore

”

“

Working at Sankalp means growth, strong team building, and a shared initiative. It creates a positive environment that inspires us to do more for our patients.

Dr. Stephy  
Clinical Pharmacist  
Bangalore

”

“

Sankalp has given me the joy of celebrating life. Being part of someone's journey and their happiness has given me the courage to embrace my own. It has sculpted me into a more beautiful human.

Archana  
Patient coordinator


”



## Mapping Impact: Transplant Service Regions in India and Beyond

### Countries Represented:

- India
- Myanmar
- Uganda
- Nigeria
- Zambia



### States Represented (India):

- Karnataka
- Andhra Pradesh
- Telangana
- Tamil Nadu
- Maharashtra
- Gujarat
- Punjab
- Rajasthan
- Madhya Pradesh (MP)
- Uttar Pradesh (UP)

### Our Partner Hospitals

- Bhagwan Mahaveer Jain Hospital, Bangalore
- Health1 Super Specialty Hospital, Ahmedabad

# Hemoglobinopathies Prevention

Preventing Today, Protecting Tomorrow – A Proactive Approach





## The Mission, Reach & Impact

### Our Vision

Every child deserves a healthy start. Our Prevention Project aims to eliminate thalassemia and sickle cell disease afflicted births by integrating screening, diagnosis, and counseling into India's public health system. Through government partnerships and expert-driven care, we empower families to make informed reproductive choices.

### Strategic Implementation

We work hand-in-hand with **State National Health Missions (NHMs)** to embed thalassemia and sickle cell screening into the **antenatal care system** at district hospitals. Our trained counselors and lab partners operate from within the government setup, ensuring sustainability and scale.

- **Key State Partners:** Madhya Pradesh, Maharashtra, Gujarat, Karnataka, Andhra Pradesh
- **Districts Covered:** 81 (up from 44 in 2022)
- **Hospitals:** 128 government-run hospitals involved
- **Counselors:** 95+ trained professionals deployed at district level
- **Lab Network:** 5 high-quality labs with capacity for 200,000+ samples annually

## FY 2024–25 Impact Snapshot



Pregnant Women Enrolled

130,273



Pregnant Women Screened

127,523



Carriers Identified

10,166

Thalassemia- 3335  
Sickle Cell- 6001  
Other- 830



Disease-Prevented Births

131

1 in every 994 pregnancies screened

High-risk Couples identified

1,252

Fetal Diagnoses completed

884

Disease-Affected Fetuses

178

Husband Screening

9,766

In prevention, we're rewriting the future reaching **1% of all births in India** and stopping a disease before it can start.

## Quality, Capacity & The Road Ahead

### Training & Capacity Building

To ensure excellence at scale, the project continuously trains and mentors its staff.

- **Regular induction & refresher trainings** for doctors, nurses, counselors & lab staff
- **Focus Areas:** Hemoglobinopathies basics, informed consent, communication, sample handling, data entry, and referral systems
- Emphasis on **empathy, cultural sensitivity**, and **building trust** with families
- Supported by **standardized SOPs**, training manuals, and ongoing evaluation

## Quality Management Systems


Sankalp's Prevention Model is powered by robust quality assurance at every step:

24 fetal medicine specialists guide diagnostic decisions remotely, ensuring no case is left behind.

**Double-reading of HPLC reports** to reduce diagnostic error

**Weekly reviews** with district teams and fetal medicine experts

**Daily tele-support** for real-time troubleshooting



**Lab metrics tracked:** Sample rejection rates, turnaround time, false-positive alerts

### Turnaround Time:

- HPLC Reports: **5.7 days**
- Fetal Medicine Reports: **3.0 days**

## Powering Prevention through Public Systems

Our multi-year MOUs with state NHMs enable a **system-wide approach** to prevention. NHMs issue clear directives for implementation, ensuring access to space, staff, and diagnostic workflows within the government setup. This approach reduces local resistance, drives acceptance, and ensures sustained program delivery.




## How Can You Contribute to the Cause?






## Mission in Motion (what we do?)



## Looking Ahead – Goals for 2025–26

Expand screening to new districts and states

Strengthen **genetic counseling** follow-ups for at-risk couples



- Leverage digital platforms like **SHeAL's LMS** for hybrid-mode training
- Improve counseling outcomes through better **audio-visual tools**

Integrate **prevention with thalassemia management** in more hospitals

Pilot **universal screening** in select blocks

## From The Frontlines

“ This work has given me the opportunity to save lives and has shaped me into a more responsible and empathetic person. I'm truly happy and proud to be a part of Sankalp India Foundation.

Abdul Wajid  
Centre Coordinator, Malegaon

“ This work brings me happiness and pride-helping people and saving the next generation from thalassemia and sickle cell. I'm thankful to Sankalp for this opportunity.

Kirti  
Centre Coordinator, Bhandara

“ I feel proud to be part of a program that helps people through free, life-saving testing. I'm grateful to Sankalp for giving me a platform to serve the nation.

Pragati Sondarva  
Centre Coordinator, Junagadh,  
Gujarat

“ After seeing the suffering of thalassemia and sickle cell patients, I made it my mission to protect the next generation. I feel proud to work for awareness and prevention.

Mohammad Amir  
Program Manager, Indore, Madhya Pradesh

“ Even families who can't afford evaluations are now being reached-our free services bring hope across 70 km stretches. I'm proud to be part of this mission towards a thalassemia-free future.


Kavitharamu  
Centre Coordinator RDT Kalyandurg

“ Being part of their mission to eliminate thalassemia and sickle cell disorders-it's something I truly feel proud to contribute to.

Dr. Prerana N Kolte  
Fetal Medicine Specialist, Chandrapur  
Maharashtra

## Mapping Impact: Districts Served by Our Prevention Centres

In prevention, we're rewriting the future reaching 1% of all births in India and stopping thalassemia in its tracks.



**81 Districts**  
**5 States**

Karnataka  
Madhya Pradesh  
Maharashtra  
Andhra Pradesh  
Gujarat



# Sankalp Labs

Empowering Thalassemia Care Through  
Precision Diagnostics



## Overview, Mission & Commitment

Sankalp Labs is a critical pillar of Sankalp India Foundation's mission to ensure comprehensive, high-quality, and accessible care for children with thalassemia. Our NABL accredited Lab with a dedicated **Pathology Lab**, a state-of-the-art **Molecular Lab**, and the recently launched **Microbiology Lab**, we support accurate diagnosis, timely intervention, and better outcomes for patients undergoing lifelong transfusions and curative treatment like Bone Marrow Transplants (BMT).

We are committed to advancing diagnostic excellence, reducing turnaround times, and scaling access to life-saving tests—because behind every sample is a child waiting for a better tomorrow.

## Pathology Lab

### Supporting Safe Transfusions and Personalized Care

- **Whopping 166754 samples were tested** in FY 2024-25 of which **133620 were HPLC samples for screening for hemoglobinopathies** and the remaining were other tests.
- We added more platforms to perform HPLC testing and a fully automated coagulation analyser this year. Additionally we added sample storage refrigerators.
- The laboratory enhanced its operational capabilities by moving to a larger space and initiating 24 hours operations.
- We have contributed towards strengthening the know-how in the field with our first paper getting published and another 2 papers under peer review. **“HPLC first approach in detecting thalassemia and other common hemoglobinopathies is more cost and time effective”** was published in the prestigious **Frontiers in Hematology** Journal.
- We have upgraded our laboratory practices to align with the latest ISO15189:2022 standard.



## Molecular Lab

### The Engine Behind Our Clinical Efforts

- **9,390 samples were tested** FY 2024-25
- We received the license to be able to test fetal samples in house with registration under the PC-PNDT Act.
- We started more inhouse tests including those for quantification of HCV virus, and Parvovirus B-19.
- We added a new 96 well extractor, and cell culture lab to be able to cater to the increasing workload.

## Microbiology Lab (Newly Launched)

### Next Frontier in Infection Surveillance and Control

- Operationalized in 2024-25 to enhance care for immunocompromised patients post-transplant
- Initial focus:
  - **Culture and Sensitivity Testing**
  - **Infection Surveillance** in transplant units
- Strengthens our ability to diagnose and combat infections in vulnerable children

#### Fast Turnaround

Internal labs drastically reduce delays in treatment



#### Cost-Efficient

Helps us serve more children while maintaining quality



### Why It Matters?

#### Integrated Care

Seamless coordination between lab, clinical, and transplant teams



#### Scalable Impact

Enables national-level screening, prevention, and cure





## Major Plans



We're developing flow cytometry tools to study immune reconstitution post-transplant, aiming to personalize treatments and minimize toxicity.




Our advancements in haploidentical transplants are paving the way for expanding our capabilities in transplant immunology.




We are introducing essential equipment to boost capacity, ensure reliability, and streamline workflows across all programs to keep up with the growth in demand for lab services.

● Pathology



● Molecular



At Sankalp Labs, we don't just process samples—we deliver precision, hope and a future free from thalassemia and sickle cell disease.



# Sankalp Hemoglobinopathy Academy of Learning (SHeAL)

Empowering the Future of Hemoglobinopathy Care

## The Vision

With thalassemia and other hemoglobin disorders affecting millions across India, the need for consistent, high-quality training is paramount. **SHeAL**, launched by Sankalp India Foundation, stands out as a national-level platform committed to **standardizing and scaling training for healthcare professionals**, volunteers, and stakeholders engaged in hemoglobinopathy prevention, management, and cure.

## Why SHeAL?



## Our Approach

SHeAL operates with a modular and scalable model, leveraging:

- Experienced faculty and practical training
- Hybrid delivery (in-person, digital, and community-based)
- A focus on real-world applicability and quality assurance
- An evolving curriculum built on field-tested knowledge

## Launch of SHeAL

### Pilot Training Program | 19–22 March 2025 | Bengaluru

To mark its launch, SHeAL hosted its first national orientation program for Hemoglobinopathy Prevention Centre Coordinators at **Bhagwan Mahaveer Jain Hospital, Vasanth Nagar, Bengaluru.**

**Participants:** 14 Centre Coordinators + 2 Regional Coordinators

**States Represented:** Madhya Pradesh, Maharashtra & Karnataka

**Purpose:** Equip participants with the skills, knowledge, and tools to scale prevention efforts across regions.

## Highlights of the 4-Day Training Program



- **Pre-Program Exposure Visit:** Insights into Sankalp Day Care Centre, Childcare Home, Blood Centre, and BMT Unit, facilitating in-person interaction with care givers, patients and family thereby promoting experiential learning.
- **Training Modules:** Each module was thoughtfully designed with participant learning at its core—starting with a topic assessment, followed by expert-led active learning, and ending with a post-session review



SHeAL used a hybrid model, blending in-person sessions with an interactive LMS to support continuous, accessible, and self-paced learning. This fostered engagement, interaction, and effective doubt clearing. A final assessment showed excellent outcomes, with nearly all participants scoring above **80%**.

- Thalassemia & Sickle Cell Disease overview
- Counselling & blood sample handling
- Fetal screening, follow-up & family support
- Data entry, compliance, HR, and finance essentials
- Strategic insights from leadership & guest faculty
- Valedictory Ceremony: Certificates distributed, recognizing the commitment of each participant.

With this program, SHeAL has set the foundation for a strong, knowledgeable, and compassionate workforce leading hemoglobinopathy prevention in their respective districts — the first step in building a **robust ecosystem for a thalassemia-free India**.

## The Road Ahead

SHeAL aims to create impactful courses and train stakeholders in hemoglobinopathy, turning graduates into lifelong learners and champions in their fields. It's more than a training platform—it's a movement to empower those who empower others.




# Our Research


## Sankalp Clinical Research Organisation

The Sankalp Clinical Research Organisation drives high-impact, ethically sound, and globally relevant research focused on improving patient outcomes, influencing health policy, and transforming clinical practice.

### Vision



### Mission




### Our Focus Areas



## Institutional Ethics Committee

*"Is this ethically safe for people?"*

Role	Name of Member
Medical Scientist	Dr. Sachin M Satpute
Social Scientist	Dr. Bijjawara H Mahesh
Member Secretary	Ms. Soumi Dutta
Legal Expert	Mr. Saurabh Chauhan
Lay Person	Mr. Sameer Nitin Thakkar
Clinician	Dr. Sangeeta Mudaliar
Clinician	Dr. Chetan Ginigeri
Clinician	Dr. Vinod Gunasekaran
Clinician	Dr. Suman Jain
Chair Person	Dr. Ashish Dhoot



## Research Advisory Committee

*"Is this good science?"*

Role	Personnel
Chairperson	Mr. Rajat Kumar Agarwal
Co-Chairperson	Dr Lawrence Faulkner
Clinical/ Laboratory Expert	Dr Sundar Periyavan
Member Secretary	Dr Tejashree Sridhar
Member	Dr Suman Jain
Member	Dr Vijay Kumawat
Member	Dr Ali Suliman



## Scientific Engagements

- Monthly Scientific Meetings
- Weekly Journal Clubs and Clinical Case Discussions
- Accelerated protocol updates and study enrolments



# Our Publications

## 2024-2025

### HPLC first approach in detecting thalassemia and other common hemoglobinopathies is more cost and time effective

Periyavan, S. ., Kumar, S. ., Mamatha, G. N., Hegde, S. ., Jain, S. ., Dhanya, R. ., ... Faulkner, L. . (2025). HPLC first approach in detecting thalassemia and other common hemoglobinopathies is more cost and time effective. *Frontiers in Hematology*, Volume 4 - 2025.


<https://doi.org/10.3389/frhem.2025.1461498>



### Granulocyte Colony-Stimulating Factor-Primed Bone Marrow Transplantation Experience in 350 Matched Sibling Donor Grafts for Severe Thalassemia

Agarwal, R. . (2025). Granulocyte Colony-Stimulating Factor-Primed Bone Marrow Transplantation Experience in 350 Matched Sibling Donor Grafts for Severe Thalassemia. *Transplantation and Cellular Therapy*.

<https://doi.org/10.1016/j.jtct.2025.01.890>



“Sankalp India Foundation has transformed care for thalassaemia through innovation and expertise, making life-saving transplants and prevention more accessible. It's been a true privilege to be associated with them. - Dr Lawrence Faulkner”

## Published Research Papers

2023

Bone Marrow Quality Index: A Predictor of Acute Graft-versus-Host Disease in Hematopoietic Stem Cell Transplantation for Thalassemia. - Transplantation and Cellular Therapy, 29(11)

2022

Is it safe and efficacious to remove central lines in pediatric bone marrow transplant patients with platelets less than 20,000/ $\mu$ l? - EJHaem, 3(1), 154-158.

Do Weekly Surveillance Cultures Contribute to Antibiotic Stewardship and Correlate with Outcome of HSCT in Children? A Multicenter Real-World Experience of 5 Years from the Indian Subcontinent. - Transplantation and Cellular Therapy, 28(3), 170.e1-170.e7.

2021

Setting up and sustaining blood and marrow transplant services for children in middle-income economies: an experience-driven position paper on behalf of the EBMT PDWP. - Bone Marrow Transplantation, 56(3), 536-543.

Pre-transplant donor-type red cell transfusion is a safe and effective strategy to reduce isohemagglutinin titers and prevent donor marrow infusion reactions in major ABO-mismatched transplants. - Annals of Hematology, 100(8), 2071-2078.

2020

The impact of Host vs. Graft mismatches on rejection of haploidentical bone marrow transplants in thalassemia patients using posttransplant cyclophosphamide. - Bone Marrow Transplantation, 55(9), 1824-1828.

Splenomegaly May Increase the Risk of Rejection in Low-Risk Matched Related Donor Transplant for Thalassemia, This Risk Can Be Partially Overcome by Additional Immunosuppression during Conditioning. - Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation, 26(10), 1886-1893.

Life expectancy and risk factors for early death in patients with severe thalassemia syndromes in South India. - Blood Advances, 4(7), 1448-1457.

2019

Information Technology-Assisted Treatment Planning and Performance Assessment for Severe Thalassemia Care in Low- and Middle-Income Countries: Observational Study. - JMIR Medical Informatics, 7(1), e9291.

Information and Communication Technology Applied to Continuing Quality Improvement for the Care and Cure of Childhood Severe Hematological Disorders in India - Blood, 134, 3468-3468.

Incidence, Risk Factors and Outcomes of Veno-Occlusive Disease / Sinusoidal Obstruction Syndrome (VOD/SOS) in Children with Severe Thalassemia (ST) Conditioned with Busulfan- Cyclophosphamide (Bu-Cy) Based Regimen - Blood, 134, 4499-4499.

Peripheral Blood to Marrow Collection White Cell Count Ratio As an Indicator of Harvest Quality and Transplant Outcomes in G-CSF-Primed Marrow Grafts - Blood, 134, 4473-4473.

Assessment of Mortality and Its Associated Risk Factors in Patients with Transfusion Dependent Thalassemia in India - Blood, 134, 973-973.

2018

Patterns of central line infections in two bone marrow transplant units in India among children undergoing allogeneic transplant for thalassaemia - Pediatric Hematology Oncology Journal, 3, S56.

Safety And Cost Effectiveness Of Removal Of Tunnelled Hickman Line Under Local Anaesthesia Vs Short General Anesthesia - Pediatric Hematology Oncology Journal, 3, S56.

Prevalence of gut colonization by Multi-Drug resistant bacteria among children with thalassemia at admission for bone marrow transplant in two transplant centers in India- Pediatric Hematology Oncology Journal, 3, S41-S42.

2017

Rejection of paternal vs maternal fully matched bone marrow grafts in children with thalassemia. - Bone Marrow Transplantation, 52(11), 1585-1586.

Multi-institutional, retrospective review of blood transfusion practices and outcomes in a large cohort of thalassemia patients in South India - Pediatric Hematology Oncology Journal, 2, 74-78.

Low-cost matched sibling bone marrow transplant for standard-risk thalassemia in a limited-resource setting - Pediatric Hematology Oncology Journal, 2, 107-113.

Can inequity in healthcare be bridged in LMICs – Multicentre experience from thalassemia day care centres in India - Pediatric Hematology Oncology Journal, 2, 88-93.

Role of G-CSF priming of donor marrow prior to transplant in low risk HLA matched sibling transplant in children with severe thalassemia - Pediatric Hematology Oncology Journal, 2, S22.

The Case for High Resolution Extended 6-Loci HLA Typing for Identifying Related Donors in the Indian Subcontinent. - Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation, 23(9), 1592-1596.

ATG vs thiopeta with busulfan and cyclophosphamide in matched-related bone marrow transplantation for thalassemia. - Blood Advances, 1(13), 792-801.

2016

Managing rare blood group requests - Bombay Oh phenotype: our experience with www.bombaybloodgroup.org. - Blood Transfusion = Trasfusione Del Sangue, 14(1), 89-90.

Complications related to blood donation: A multicenter study of the prevalence and influencing factors in voluntary blood donation camps in Karnataka, India. - Asian Journal of Transfusion Science, 10(1), 53-8.

2015

A study of the noncompliance of blood banks on safety and quality parameters in blood donation camps in Bengaluru. - Asian Journal of Transfusion Science, 9(1), 23-8.

2014

A prospective international cooperative information technology platform built using open-source tools for improving the access to and safety of bone marrow transplantation in low- and middle-income countries. - Journal of the American Medical Informatics Association : JAMIA, 21(6), 1125-8.

**CLICK THE LINK  
TO READ THE  
FULL ARTICLES**



# People & Culture 2024

## Empowering People, Powering Success

At Sankalp, we believe that when people grow, impact grows. In 2024, we deepened our commitment to building a workplace where every individual feels valued, heard, and supported. We're so proud that **165 of our 277 team members are women**, reflecting our commitment to inclusion and empowerment in our mission. From leadership development to wellness programs, here's how we're powering people to fuel our mission:

### Leadership Development

- Launched the **Agile Leadership Program** to equip emerging leaders with empathy, resilience, and vision.
- Focused on building future-ready teams with strong communication and people-first thinking.

### Training & Development

- Introduced the Sankalp Hemoglobinopathy Academy of Learning, a dedicated training platform for people working in the field of hemoglobinopathies.
- Designed to promote continuous learning, innovation, and excellence through skills and certification programs.

### Talent Acquisition

- Welcomed **197 new team members** across functions including doctors, nurses, analysts, and quality professionals.
- Focused on bringing in talent that aligns with our mission and values.





### Health, Wellness & Benefits

- Rolled out support programs including **medical reimbursements, loan assistance, and hostel facilities.**
- Prioritized employee well-being to support health, stability, and work-life balance.

### Engagement & Connection


- Hosted the **Annual Coordinators' Meet**, a platform to share, connect, and celebrate.
- Organized team outings that boosted morale, strengthened bonds, and recharged spirits across teams.
- Result: noticeable improvement in team satisfaction and collaboration.

### Looking Ahead


We continue to build a culture where people thrive and grow, both personally and professionally. As we grow together, we move one step closer to our shared goal: **A Thalassemia-Free India.**

## 2024 - 2025: Total Headcount - 277


### Workforce by Location



### Workforce by Project



### Workforce by Gender



# Touching Hearts, One Smile at a Time

At Sankalp, volunteering is more than just a gesture — it's a spark that lights up lives. When individuals, groups, and institutions choose to spend time with our children, they bring more than joy; they leave behind lasting impressions and precious lessons.

These moments go far beyond play and interaction. Volunteers are immersed in the journey of a child with a blood disorder — witnessing firsthand the critical role of blood transfusions through guided visits to our blood bank and daycare centres. They learn not only how blood saves lives, but why every single drop matters.

As they sing, dance, tell stories, solve puzzles, and laugh with the children, volunteers become part of something significant. They gain awareness about thalassemia and sickle cell disease, not just through medical facts, but real stories of strength and survival.

The experience often leaves a profound mark. Many walk in unaware, and leave as informed advocates, often first-time blood donors, now committed for life. They carry home a heart full of gratitude, a changed perspective, and a smile that says it all — because in giving, they too received something priceless.



# Our Donors

At Sankalp India Foundation, we know that every step forward in our mission to cure children is made possible because of our donors. Your support gives us the strength and resources to reach more children, offer them a chance at life, and bring their families hope. Thank you for being such an essential part of this journey.

## Government, Corporate and Institutional Donors

Aditya Steel	Huron Eurasia India Private Limited	Pahuja Trust
Association Of Muslim Profession	Hyderabad, Chief Minister's Relief Fund	Pall India Pvt Ltd
Aurangabad Educational and Welfare society	Impact Guru technology Vetures	Pray Foundation Trust
Bulk Liquid Solution Pvt Ltd	Inamdar Nursing Home	Radhe Enterprise
Chief Minsters Relief Fund, Maharashtra	Invitrogen BioServices India Pvt. Ltd	Radico Fibers
Cholamandalam Investment and Finance Company Limited	Jai Shivshakti Health & Education Foundation	Rama Charitable Trust
Cipla Foundation	JFrog India Pvt Ltd	Samrat Share And Care Association
Cure2Children Foundation, Italy	Kantipudi Steels Pvt	Electrotherm (India) Ltd
Cytiva Hyclone Life Sciences Solutions India Private Limited	Karnataka State wakf foundation member secretary	Sanofi Healthcare India
Dell Employees	Karo Trust	Shiv Hari Sarees
Deutsche Bank	Khalsa Aid International	Shree Jalaram Abhyuday Sadbhavna Trust
Deutsche India Private Limited	Kote Foundation (Right to Live)	Srikem Laboratories Pvt. Ltd
DKMS Group gGmbH	Lake Chemicals Pvt Ltd	STCI Primary Dealer
Doctor's for Seva	Life line foundation	Sun Pharma Laboratories Limited
Evershine Floor	Lodha International LLP	Suprajit Engineering Limited
Flipkart Employees	M K Hamied Foundation	Thalassemia and Sickle Cell Society
Friends Charitable Trust	Madhulika Foods Pvt Ltd	Thalassemia Bal Seva Yojna
GT US Knowledge and Capability Center India Private Limited	Malharbai Foundation	The Lifeline Foundation Trust Charity
Gujarat, Prime Minister's National Relief Fund	Microsoft	The Royal world Hopitality
Haridas Ramji Davda Charitable Trust	Narola Diamonds Pvt Ltd	UK Online Giving Foundation
HDFC	NETAJI SUBHASH CHANDRA	Universal Communication
Himalaya Wellness Company	Online Giving Foundation	Vasant Atma Charitable Trust
	Oracle	

## Individual Donors

Amit Sedai	Kedar Sudhir Gokhale	S V Iyer
Anil Datta Kumar B	Kruti Joshi	Sameer Nitin Thakkar
Ankit Poddar	Lamitha	Sanaga Sarayu
Archana	Leela S Iyer	Sangamita
Ganga Badan Roy	Manohar Bahal Dinesh pal	Saryu Chaudhry
Gangadharaiah M	Mohan V S	Shree Vardhaman Parivar
Chanshyamsinh Vaghela	Naresh Jain	Shyam Agarwal
Gopumadhavan	Rajesh Arvikar	Tvisha Vijay Gajaria
Govindan	Rana Ajay Singh	Umah Agarwal
Jagadeesh B A	Renu Chellani	Vijay Shankara
Jagadeesh SS	Rishi Ashok Kapoor	Vikassinh Pravinsi
Karthik Jain	Rohit Agarwal	



# Transparency Disclosures

Dr Sundar Periyavan is Member of the Executive Committee beside the remunerated position as the Lab Director, Sankalp Labs. No remuneration, sitting fees or any other form of compensation was paid to any other board member or volunteers.

We have 226 salaried employees in Karnataka (110), Maharashtra (40), Gujarat (40) and Madhya Pradesh (36).

Kumari Ankita and Rajat Kumar Agarwal are board members who are married to each other.

Dr Lawrence Faulkner is the Advisor to the board and the Medical Director of the organisation in a non-remunerative basis.

Name	Designation	Gender	Employment	Contact
Rajat Kumar Agarwal	President	Male	CEO, Jagriti InnoHealth Platforms	rajat@sankalpindia.net
Amit Sedai	Secretary	Male	Software Professional, Jagriti InnoHealth Platforms	amit@sankalpindia.net
Kumari Ankita	Treasurer	Female	Software Professional, Jagriti InnoHealth Platforms	ankita@sankalpindia.net
R N Prasad	Board Member	Male	CEO at Confluence Consulting Circle and Partner - Spice Catalyst USA	rnp@confluenceconsulting.in
Dr Sundar P	Board Member and Lab Director	Male	Lab Director at Sankalp India Foundation	sundarp@sankalpindia.net
Venugopal B	Joint Secretary	Male	Official @ Indian Postal Department	venu@sankalpindia.net
Jayesh Parmar	Board Member	Male	Entrepreneur at Swastik Solar	jayeshparmar83@gmail.com
Dr. Lawrence Faulkner	Advisor to the Board and Medical Director	Male	Medical Coordinator at Cure2Children Foundation and Sankalp India Foundation, Consultant DKMS Group	lawrence.faulkner@cure2children.org
Sundaresan V Iyer	Advisor to the Board	Male	H R Consultant at Cipla Ltd	iyersvi@yahoo.co.in

## Name and Address of Bankers:

**Punjab National Bank-** Jayanagar, Bangalore

**HDFC Bank-** Banerghatta Road, Bangalore

**INDIAN BANK-** HSR Layout, Bangalore


**IDFC Bank-** Jayanagar, Bangalore

**State Bank Of India-** Sansad Marg, New Delhi


# Our Financials

## Projectwise Expenditure


### Voluntary Blood Donation




### Thalassemia Management




### Thalassemia Cure




### Thalassemia Prevention



### Miscellaneous



### Expenditure 2024-2025



## Balance Sheet for the Year Ending on 31st March 2025

### SANKALP INDIA FOUNDATION - BANGALORE

#### BALANCE SHEET AS AT 31ST MARCH, 2025

LIABILITIES	as at 31/03/2025	as at 31/03/2024	ASSETS	as at 31/03/2025	as at 31/03/2024
<b>CORPUS FUND</b>			<b>CAPITAL ASSETS</b>		
Opening Balance as on 01.04.2008	43,760	43,760	As per Schedule "I"	14,26,97,785	15,43,02,010
<b>RESTRICTED FUNDS</b>			<b>CURRENT ASSETS</b>		
As per Schedule "II"			Cash in Hand	-	-
Fixed Assets Capital Fund	9,56,78,437	10,54,75,223	Balance With Bank	1,67,39,995	59,21,651
Unutilised Fixed Assets Capital Fund	40,17,535	-	IT Refund	10,02,605	5,38,873
			Security Deposit	1,55,27,500	85,92,500
Surplus/ (Deficit) - Current Year	-1,12,02,994	2,39,96,464	Loan to Employee	3,46,848	3,31,843
Surplus/ (Deficit) - from Previous Years	10,37,95,917	7,97,99,453	Advance to Suppliers	6,08,441	8,32,760
	<b>19,23,32,655</b>	<b>20,93,14,900</b>	Prepaid Expenses	1,64,674	1,17,768
				<b>3,43,90,063</b>	<b>1,63,35,395</b>
<b>CURRENT LIABILITIES &amp; PROVISIONS</b>			<b>INVESTMENTS</b>		
Expenses Payable- Sundry Creditors	1,54,73,274	21,81,278	Fixed Deposit	3,24,83,926	4,19,13,419
Gratuity Payable	10,82,122	15,35,986	Add: Interest Accrued on FD for CY	11,75,234	16,28,383
Professional Tax Payable	7,600	6,800		<b>3,36,59,160</b>	<b>4,35,41,802</b>
ESI Payable	4,286	8,163			
Provident Fund Payable	1,90,456	1,72,858			
TDS Payable	16,56,614	9,59,221			
	<b>1,84,14,353</b>	<b>48,64,306</b>			
<b>Total</b>	<b>21,07,47,008</b>	<b>21,41,79,207</b>	<b>Total</b>	<b>21,07,47,008</b>	<b>21,41,79,207</b>

Significant Accounting Policies and Notes on accounts as per annexure attached.

as per our separate report of even date annexed

Date:

Place: Bangalore

UDIN: 25231265BMOPOB8473

## Income & Expenditure for the Year Ending on 31st March 2025

### SANKALP INDIA FOUNDATION - BANGALORE

#### INCOME & EXPENDITURE ACCOUNT FOR THE YEAR ENDING ON 31ST MARCH, 2025

EXPENDITURE	Notes	for the Year ended 31/03/2025	for the Year ended 31/03/2024	INCOME	for the Year ended 31/03/2025	for the Year ended 31/03/2024
To Operational Expenses	1	27,55,072	16,52,648	By Bank Interest	11,96,431	10,09,225
To Expenses on Project Disha		-	11,71,399	By Contribution towards Sankalp Labs	14,37,765	62,45,349
To Rakta Kranti		-	16,28,076	By Contribution towards Thalassemia Cure	16,75,98,237	13,58,88,818
To Thalassemia & Sickle Cell Prevention and Research	2	7,35,36,091	1,73,46,468	By Contribution towards Thalassemia Management	6,79,15,715	3,71,01,686
To Thalassemia Cure Expenses	3	16,42,81,463	10,98,12,598	By Thalassemia & Sickle Cell Prevention and Research	7,12,44,123	1,75,55,500
To Thalassemia Management Expenses	4	6,49,18,544	3,30,64,407	By Contribution towards Sankalp Blood Center	1,28,24,582	44,28,394
To Sankalp Labs	5	-	30,371	By General Contribution	21,77,756	5,87,463
To Sankalp Blood Center	6	2,19,09,998	1,17,18,471	By Contribution towards Events	-	9,900
To Clinical Research Expenses		2,03,294	-	By Interest Received on FD's	31,35,365	18,38,049.00
To Event Expenses		8,58,174	1,13,117	By Interest Received on IT Refund	12,263	4,214
To Fixed Assets Discarded		0	35,89,577	By Refund from Supplier	95,000.00	-
To Deposits Written off		-	5,45,000	By Deficit	8,25,398.82	-
				(Excess of Expenditure over Income)		
To Surplus		-	2,39,96,464			
(Excess of Income over Expenditure)				By Fixed Assets Capital Fund - Amortisation	5,00,85,233	-
				(incl. accumulated amortisation since 01.04.2020)		
To Depreciation		5,89,74,603		By Adjustment to Fixed Assets	-14,88,225	-
(incl. all Accumulated Depreciation)						
				By Net Deficit	1,12,02,993.77	
				(Excess of Expenditure over Income)		
		<b>38,74,37,238</b>	<b>20,46,68,598</b>		<b>38,74,37,238</b>	<b>20,46,68,598</b>

Significant Accounting Policies and Notes on accounts as per annexure attached.

As per our separate report of even date,

Date:

Place: Bangalore

UDIN: 25231265BMOPOB8473



# Join in the Revolution

Together we can do more. Adopt a child for thalassemia management, support the nourishment of a family or make a general contribution towards our work.

Craving for an opportunity to bring in a change for the better?

Connect with us to explore opportunities to work together.



CONTRIBUTE TO

## Sankalp India Foundation

Scan QR Code below with your PSP App



Or Pay to VPA

*SIF@idfcbank*



# Organizational Flowchart

